AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2020
Oct 2, 2020
33861_dirs_2020-10-01_a044895a-f9e1-43c5-94f9-201100239713.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2020-10-01
Reporting Person: Fisher Stewart (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 85372 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $2.11 | 2026-07-12 | Common Stock (9485) | Direct | |
| Stock Option (Right to Buy) | $3.72 | 2028-04-23 | Common Stock (71144) | Direct | |
| Stock Option (Right to Buy) | $4.98 | 2030-07-02 | Common Stock (204397) | Direct | |
| Stock Option (Right to Buy) | $4.98 | 2030-07-08 | Common Stock (74080) | Direct |
Footnotes
F1: Represents underlying unexercised stock options that were granted on July 13, 2016. The terms of the original grant provide that 20% of this option vested and became exercisable on May 2, 2017, with the remainder vesting in 16 equal quarterly installments thereafter.
F2: Represents underlying unexercised stock options that were granted on April 24, 2018. The terms of the original grant provide that 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter.
F3: This option shall vest and become exercisable in 20 equal quarterly installments, with the first installment vesting on September 5, 2020.